WALTHAM, MA. — November 7, 2018 — Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that management will present at two investor conferences in November as follows:
|Conference||Stifel 2018 Healthcare Conference|
|Date||Wednesday, November 14, 2018|
|Time||12:30 p.m. Eastern Standard Time|
|Location||Lotte New York Palace Hotel, NYC|
|Presenter||David Long, Chief Financial Officer|
|Conference||Canaccord Genuity Medical Technologies & Diagnostics Forum|
|Date||Thursday, November 15, 2018|
|Time||2:30 p.m. Eastern Standard Time|
|Location||Westin Grand Central Hotel, NYC|
|Presenters||Mark Toland, President and Chief Executive Officer and David Long, Chief Financial Officer|
The presentations will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the company’s website at investors.corindus.com, under the News & Events Section.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath® System is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and vascular procedures. During the procedure, the interventionalist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-bymillimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. CorPath GRX is the second generation robotic-assisted technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. For additional information, visit www.corindus.com, and follow @CorindusInc.